|Videos|October 18, 2019

Assessing NICU Stewardship Needs in South Africa

Pavel Prusakov, PharmD, highlights how he educated pharmacists from South Africa to lead antimicrobial stewardship programs in the NICU with Pablo J. Sánchez, MD, and Debra Goff, PharmD.

Segment Description: Pavel Prusakov, PharmD, NICU clinical coordinator, in the Department of Pharmacy at Nationwide Children’s Hospital highlights how he educated pharmacists from South Africa to lead NICU antimicrobial stewardship programs.

Interview transcript: (modified slightly for readability)

So Debbie [Goff] and I went to South Africa to assess the educational needs of pharmacists to participate in antimicrobial stewardship programs and to become really an integral part of it in South Africa. When we went to some of the units, what I saw is that they use last line antibiotics pretty much on a daily basis, whereas for me, in my career, I've never seen colistin use in a NICU. So that was very striking to me.

We picked 4 pharmacists to be thought leaders in South Africa and took them to train with me at Nationwide Children's and to see how the antimicrobial stewardship program for our NICUs run. We have 7 NICUs across the city of Columbus, covering over 290 NICU beds. Those pharmacists trained with me to really understand how pharmacists can make a difference and antimicrobial stewardship program in their own country and lead the efforts in their country for everybody else and educate all the other pharmacists.

View part 1 and part 2 of this interview.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.